Neostigminemethylsulfaat Cf (Neostigmine Methylsulfate)

Neostigmine methylsulfate, the active ingredient in Neostigminemethylsulfaat Cf, is an acetylcholinesterase inhibitor presented as a sterile injectable solution for intramuscular, intravenous, or subcutaneous use. It is employed to improve neuromuscular transmission in conditions such as myasthenia gravis, to stimulate gastrointestinal motility after surgery, and to aid bladder emptying in urinary retention.

GNH USA supplies Neostigminemethylsulfaat Cf as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Neostigmine methylsulfate acts on the cholinergic system and is indicated for several parasympathomimetic applications.

- Myasthenia gravis: enhances neuromuscular transmission, reducing muscle weakness. - Postoperative ileus: stimulates intestinal peristalsis to restore bowel function after surgery. - Urinary retention: promotes bladder muscle contraction to facilitate voiding.

Neostigmine methylsulfate may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea and vomiting - Diarrhea or abdominal cramps - Increased salivation - Muscle fasciculations - Sweating or flushing

Serious or Rare Side Effects: - Bradycardia or heart block - Bronchospasm or severe asthma exacerbation - Cholinergic crisis with respiratory muscle weakness - Seizures or convulsions - Anaphylactic reactions

Neostigmine methylsulfate requires careful patient assessment and monitoring to minimise risks.

- Dose adjustment in renal impairment: reduce dose or monitor closely. - Monitor for cholinergic crisis: watch for muscle weakness and respiratory depression. - Avoid in patients with hypersensitivity to neostigmine or excipients. - Caution in asthma or COPD: may provoke bronchospasm. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Neostigmine methylsulfate can interact with several drug classes, influencing its efficacy or safety.

Major Interactions (Avoid): - Nondepolarizing neuromuscular blockers: may potentiate blockade. - Anticholinergic agents: may reduce therapeutic effect. - Beta‑blockers: may enhance bradycardia.

Moderate Interactions (Monitor Closely): - Aminoglycoside antibiotics: may increase neuromuscular weakness. - Cardiac glycosides: may increase risk of bradyarrhythmias. - Other cholinesterase inhibitors: additive cholinergic effects.